Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and symptoms in adults with symptomatic ...
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about any scientific advance. It is the ...
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies. Several such molecules, such as RSL3, work ...
Addition Therapeutics came out of stealth mode to highlight its Precise RNA-Mediated Insertion of Transgenes (PRINT) gene ...
Peptidream Inc. has announced progression of an oral dual IL-17A and IL-17F macrocyclic peptide inhibitor for psoriasis, with ...
Nchroma Bio Inc. has received a certificate for clinical trial in Hong Kong to initiate a first-in-human phase I/II trial of ...
Much has been made of the recent skyrocketing of Medicare spending on skin substitutes, but a new enforcement action by the U ...
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European ...
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to ...
Companion Spine SAS received premarket approval from the U.S. FDA for its DIAM spinal stabilization system, for treatment of ...
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting ...
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback